BNT327 Takes Leading Role In BioNTech’s Oncology Strategy In Q3

The biotech company is pushing the anti-PD-L1xVEGF-A bispecific antibody into Phase III, where it has potential to beat Akeso/Summit’s ivonescimab to market.